JA IDIQ Redacted version

CUI
Control Number: FY26-0683

chemistry analysis program. Navy personnel rotating into the Naples hospital have already received training while at other Navy hospital commands on the Vitros systems and use of a different system will risk impact to the quality and timeliness of patient care. Thus, investing in a different line of equipment would result in substantial duplication of cost to the Government that is not expected to be recovered through competition. Therefore, only one responsible source exists and no other competitive sources can fulfill the requirement. Award of a sole-source contract to CIDICHEM is mission-critical to prevent a disruption in essential medical services at USNH Naples.
CIDICHEM SRL is the only authorized seller and lessor of the Ortho Clinical Diagnostics instruments. CIDICHEM reagents and supplies are used to perform dry-slide technology diagnosis testing via the Vitros 5600 testing equipment. The CIDICHEM supplied reagents are the only authorized products to be utilized by the Vitros 5600. The tests and instruments are used to provide critical care immunochemistry on patients, as requested by health care providers. This critical care testing includes cardiac markers, liver enzymes, kidney function and other testing needed for emergent patient care, which is essential to successful hospital operations United States Naval Hospital (USNH) Naples operates two Ortho Vitros 5600 chemistry analyzers, which are critical to our clinical laboratory and patient care mission. These analyzers were installed in 2023 and remain well within their operational life expectancy. Continued operation of this equipment is essential for providing in-house chemistry testing capabilities. The current support contract is projected to exhaust all funding within the next three months, necessitating the immediate award of a new contract to ensure seamless continuation of services. Upon contract approval and execution, the Contractor (CIDICHEM) shall conduct a comprehensive validation study of green top tubes to verify their clinical suitability for all designated laboratory assays on the Ortho Clinical Diagnostics VITROS 5600 analyzers. This rigorous assessment must evaluate sample integrity, compatibility with existing laboratory instrumentation, and overall analytical performance across all relevant assays. To ensure strict adherence to patient safety protocols, no green top tubes shall be utilized for live patient testing until U.S. Naval Hospital Naples has successfully reviewed and formally accepted the validation